# Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)

> **NCT04406870** · PHASE4 · UNKNOWN · sponsor: **Shanghai Children's Medical Center** · enrollment: 36 (estimated)

## Conditions studied

- Hemangioendothelioma of Liver

## Interventions

- **DRUG:** Sirolimus Oral Product
- **DRUG:** propranolol

## Key facts

- **NCT ID:** NCT04406870
- **Lead sponsor:** Shanghai Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406870, "Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04406870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*